사이언스 바이오메디칼(PBM)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $6.50 (+2.85%), 시가총액 $0.01B, 52주 최저~최고 $0.63 ~ $11.50.
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted ps
사이언스 바이오메디칼의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
사이언스 바이오메디칼의 현재 주가는 $6.50 (+2.85%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
사이언스 바이오메디칼의 시가총액은 약 $0.01B입니다.
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with a